Tandem Pumps + CGMDexcom G7 Integration
Choose Your Pump
Dexcom G7 is approved for use with either the Tandem Mobi system or t:slim X2 insulin pump.
Goodbye Fingersticks
For calibration or mealtime dosing, when our insulin pumps are paired with Dexcom G7 CGM.†
Simple Auto-Applicator
A one-touch applicator easily inserts a small sensor with no visible needle.
Faster Sensor Startup
Spend more time in closed loop with shorter wait times between sessions.‡
10-Day Sensor Wear§
Reduces the number of times that the sensor needs to be replaced.
Trusted Partners
More than 10 years of collaboration between Tandem and Dexcom.
People who combine a CGM with automated insulin delivery have the best overall glucose control compared to multiple daily injections and standard pump therapy.2
What's next?
Whether you're ready to get a Tandem insulin pump, or looking to check insurance coverage, you’ll find everything you need here.
Existing Tandem Pump Users
Users with an in-warranty Tandem insulin pump can update their pump software to integrate with a Dexcom G7 sensor.^
Check Sensor Compatibility
Already have a Dexcom G7 sensor? Review a breakdown of what versions are compatible with your insulin pump before updating.
Complete Required Steps
You may need to complete required training or other steps to update the software on your pump. Log in to your account for details.
* CGM sold separately.
† If glucose alerts and Dexcom CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
‡ Faster claim based on two-hour warmup time with the Dexcom G6 sensor vs. 30-minute warmup time with the Dexcom G7 sensor.
§ Why is Tandem not yet compatible with the Dexcom G7 15 Day sensor? Each new sensor generation requires validation, and software update for insulin pump integration. Because the G7 15 Day sensor features a one-hour startup time, new software development will be required to ensure Tandem pump and mobile app display the correct warm-up information. Our goal is always to maintain the highest standards of safety, reliability, and performance. Once the necessary updates and testing are complete, we plan to enable compatibility with the 15-day G7 through a future software update, just as we've done successfully with past CGM iterations.
^ Future updates for all or some Tandem products may not be developed and may not be offered everywhere and would be subject to applicable regulatory approvals. Software updates are only available to customers who are in warranty at the time they update their pump. Additional training may be required to access certain software updates. Charges may apply. Tandem may discontinue select software and features over time at its discretion.
References
1. Dexcom G7 User Guide, 2024.
2. Nørgaard K, Ranjan AG, Laugesen C, et al. Glucose Monitoring Metrics in Individuals with Type 1 Diabetes Using Different Treatment Modalities: A Real-World Observational Study. Diabetes Care. 2023;dc231137. doi: 10.2337/dc23-1137.
Important Safety Information
RX ONLY.
Indications for Use
Tandem Mobi system: The Tandem Mobi insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The Pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater.
t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater.
Control-IQ+ technology: Control-IQ+ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ+ technology is intended for the management of type 1 diabetes mellitus in persons 2 years of age and greater and of type 2 diabetes mellitus in persons 18 years of age and greater.
Warning: Control-IQ+ technology should not be used in anyone under the age of 2 years old with type 1 diabetes or under the age of 18 years old with type 2 diabetes. It should also not be used in patients who require less than a total daily insulin dose of 5 units of insulin per day or who weigh less than 20 pounds (9 kilograms), as those are the required minimum values needed for Control-IQ+ to operate safely.
Users of the pump and Control-IQ+ must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use. Failure to follow these instructions for use could result in an over delivery or under delivery of insulin. This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Visit tandemdiabetes.com/safetyinfo for additional important safety information.